Skip to main content
main-content

Rheumatology

Latest articles

15-07-2020 | Rheumatology | News | Article

PRIME cells may be a biomarker of imminent rheumatoid arthritis flares

Blood transcriptional profile changes and the presence of a novel cell type – termed PRIME cells – may be indicative of an impending flare in patients with rheumatoid arthritis, suggest findings from a longitudinal genomic analysis published in The New England Journal of Medicine.

14-07-2020 | Rheumatology | News | Article

IL-6 inhibitors show potential for COVID-19

Add-on treatment with an IL-6 receptor inhibitor warrants further investigation for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest preliminary findings from two Italian observational studies published in the Annals of the Rheumatic Diseases.

13-07-2020 | Rheumatology | News | Article

FDA adds hypersensitivity warning to baricitinib label

The US FDA has added a precaution to the label for baricitinib advising of a possible risk for reactions including angioedema, urticaria, and rash that may reflect drug hypersensitivity.

13-07-2020 | Rheumatology | News | Article

Vitamin D and omega-3 unwarranted for pain reduction in knee osteoarthritis

Vitamin D and marine omega-3 fatty acid supplements are unlikely to improve chronic knee pain associated with osteoarthritis, suggests an analysis of the randomized VITAL trial.

10-07-2020 | Rheumatology | News | Article

Addressing residual symptoms remains an unmet need in RA management

Some patients with rheumatoid arthritis continue to experience residual symptoms despite achieving treat-to-target goals, but there is a paucity of evidence on the exact prevalence of these symptoms and their impact, report the authors of a systematic review.

10-07-2020 | Rheumatology | News | Article

RA, SLE associated with COVID-19 mortality risk in large UK study

A large UK study using the OpenSAFELY analytics platform has identified autoinflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus as possible risk factors for COVID-19-related death.

09-07-2020 | Rheumatology | News | Article

Smartphone app could aid pain management in JIA

A smartphone-based pain self-management program – iCanCope with Pain  – warrants further investigation in adolescents with juvenile idiopathic arthritis following a successful pilot trial, researchers report.

08-07-2020 | Rheumatology | News | Article

‘Minor differences’ between biologics for the treatment of RA

A systematic review and network meta-analysis finds few significant differences in the benefits and harms associated with different biologics when given in combination with methotrexate for the treatment of rheumatoid arthritis.

08-07-2020 | Rheumatology | News | Article

SELECT-EARLY: Better RA outcomes with upadacitinib vs methotrexate

Treatment with the JAK inhibitor upadacitinib leads to significantly better clinical and radiographic outcomes than methotrexate therapy among patients with moderate-to-severe rheumatoid arthritis who have no or limited prior methotrexate exposure, show the SELECT-EARLY results.

07-07-2020 | Rheumatology | News | Article

COVID-19: SLE patients, physicians report problems with hydroxychloroquine access

Findings from two studies suggest that patients with systemic lupus erythematosus across multiple countries have experienced issues with accessing hydroxychloroquine during the COVID-19 pandemic.

06-07-2020 | Rheumatology | News | Article

Synovial macrophage subsets may predict RA flare risk

Different subsets of macrophages in the synovial tissue could help predict whether patients with rheumatoid arthritis will experience flares following treatment discontinuation, researchers report in Nature Medicine.

03-07-2020 | Rheumatology | News | Article

EMA approves subcutaneous infliximab for PsA, ankylosing spondylitis

Click through for more details about this expanded indication

03-07-2020 | Rheumatology | News | Article

Study demonstrates real-world effectiveness of certolizumab pegol for axSpA

Treatment with certolizumab pegol is beneficial for patients with axial spondyloarthritis in real-world clinical practice, suggest findings from the CIMAX study.

02-07-2020 | Rheumatology | News | Article

Colchicine shows potential for COVID-19

Preliminary findings from the GRECCO-19 trial suggest that colchicine, an anti-inflammatory drug used in the treatment of gout and familial Mediterranean fever, may have potential as a therapeutic agent for COVID-19.

01-07-2020 | Rheumatology | News | Article

Heightened risk for self-harm with some rheumatic diseases

Patients with rheumatic diseases, particularly fibromyalgia, have elevated rates of self-harm, according to data from the Clinical Practice Research Datalink.

01-07-2020 | Rheumatology | News | Article

ACR clarifies support for telemedicine in rheumatology during and after COVID-19

The American College of Rheumatology has issued a position statement supporting the use of telemedicine during and after the COVID-19 pandemic.

30-06-2020 | Rheumatology | News | Article

Age at biologic DMARD initiation impacts adverse event risk

The likelihood of experiencing an adverse event after initiating treatment with a first biologic DMARD increases with age and is higher in women than men, show data from a real-world study among people with rheumatic diseases.

29-06-2020 | Rheumatology | News | Article

COVID-19 lockdown has ‘significant consequences’ for SpA patients

Home confinement during the COVID-19 pandemic is associated with a reduction in medication intake and a worsening of disease activity among patients with spondyloarthritis, survey results suggest.

29-06-2020 | Rheumatology | News | Article

COVID-19: Support for further investigation of tocilizumab

Add-on treatment with the IL-6 inhibitor tocilizumab may improve outcomes for patients with severe COVID-19, suggest findings from two retrospective cohort studies.

26-06-2020 | Rheumatology | News | Article

Noninferiority of diacerein to celecoxib demonstrated for knee OA pain

Diacerein has comparable efficacy to celecoxib for pain reduction in patients with moderate-to-severe symptomatic knee osteoarthritis and is well tolerated, suggest study findings reported in Rheumatology.

Image Credits